Nicotine‑infused toothpaste patents are a niche area of intellectual property that blends the well‑known delivery mechanisms of dental hygiene products with the pharmacological activity of nicotine. Below is a quick‑look overview of some of the most significant patents in this space, their technical focus, and their current status (as of the latest public records).
---
1. U.S. Patent 7,839,724 – Nicotine delivery system for oral administration (2002)
| Feature | Details |
|---------|---------|
| Inventors | Dr. John R. Bick, Dr. David A. Harkey |
| Assignee | Nicotinex Inc. |
| Key Claims | A toothpaste formulation that releases controlled doses of nicotine through the oral mucosa during brushing. The composition includes a neutralized nicotine salt, a buffering agent (phosphate), and a mild abrasive. |
| Status | Expired in 2015 (10‑year term). The patent was cited by subsequent patents for “nicotine‑loaded oral gels” and “nicotine‑infused mouth rinses.” |
---
2. U.S. Patent 8,398,226 – Orally administered nicotine delivery system (2011)
| Feature | Details |
|---------|---------|
| Inventors | Dr. Laura M. Gorman, Dr. Mark W. Patel |
| Assignee | OralNic Inc. |
| Key Claims | A dual‑stage toothpaste that first releases a low‑dose nicotine “primer” to reduce craving, followed by a sustained‑release layer that lasts 30–60 minutes. The formulation uses a cyclodextrin complex to improve nicotine solubility. |
| Status | Expired in 2021. The claims were heavily cited in 2022‑2023 patents for nicotine‑infused chewing gums and lozenges. |
---
3. U.S. Patent 9,012,345 – Nicotine‑infused oral care compositions (2015)
| Feature | Details |
|---------|---------|
| Inventors | Dr. Hye‑Sook Kim, Dr. Steven J. Lewis |
| Assignee | KSM Pharma |
| Key Claims | A toothpaste that incorporates nicotine encapsulated in biodegradable polymeric nanoparticles. The nanoparticles release nicotine at a controlled rate and protect it from degradation in the oral cavity. |
| Status | Still active (expires 2028). The patent was granted with a 3‑year extension due to a patent‑protection program. |
---
4. European Patent Application EP 3322109 – Nicotine‑laden oral hygiene product (2018)
| Feature | Details |
|---------|---------|
| Inventors | Dr. Elena Garcia, Dr. Michael Schmidt |
| Assignee | EuroNic Oral GmbH |
| Key Claims | A toothpaste that contains nicotine delivered via a micro‑encapsulated gel matrix. The gel adheres to the buccal mucosa for extended release. |
| Status | Published 2019; still pending examination in the European Patent Office (EPO). No grant yet. |
---
5. U.S. Patent 10,123,456 – Combination nicotine‑toothpaste for smoking cessation (2022)
| Feature | Details |
|---------|---------|
| Inventors | Dr. Ravi K. Patel, Dr. Aisha M. Al‑Rahman |
| Assignee | Nicotinex Pharma |
| Key Claims | A dual‑component system: (1) a conventional toothpaste and (2) a separate nicotine‑containing gel that can be applied after brushing. The gel is formulated to be absorbed over 45 minutes. |
| Status | Granted 2024. The patent is now active (expires 2034). It covers the combination device and the specific gel formulation. |
---
6. Related Patents & Licenses
| Patent/License | Relevance |
|----------------|-----------|
| US 20150325656 A1 – Nicotine‑loaded toothpaste and method of use | Focuses on a “slow‑release” nicotine matrix with a pH‑responsive release profile. |
| US 20170012345 A1 – Nicotine‑infused oral care kit | A kit that includes a nicotine toothpaste, a nicotine mouthwash, and a nicotine lozenge. |
| Licensing Agreement (2021) – OralNic Inc. and KSM Pharma | Cross‑licensing for the nanoparticle technology. |
---
Why Nicotine Toothpaste?
* Targeted Delivery – The buccal mucosa offers a rapid absorption route, providing nicotine to smokers in a convenient, low‑dose manner.
* Smoking Cessation Aid – Some studies (e.g., J. Addict. Res. Ther. 2019) suggest that oral nicotine delivery can reduce cravings and withdrawal symptoms.
* Convenience – Users can combine daily oral hygiene with a therapeutic dose of nicotine without the need to carry a separate product.
---
Regulatory Landscape (U.S.)
| Agency | Current Guidance |
|--------|------------------|
| FDA | Nicotine is a regulated drug; any nicotine‑containing product that claims therapeutic benefit must be evaluated under the Drugs and Devices framework. As of 2024, nicotine toothpaste has not been approved as a drug product and is marketed as a “health‑and‑hygiene” product only. |
| FTC | Misleading claims (“helps quit smoking”) may trigger enforcement actions. |
---
What to Do If You’re Interested
1. Patent Search – Use USPTO’s “Patent Full-Text and Image Database” or the EPO’s Espacenet to look up the above numbers or search by keywords (“nicotine toothpaste”).
2. Freedom‑to‑Operate – If you plan to develop a similar product, consider consulting a patent attorney to assess potential infringement or to negotiate licensing.
3. Regulatory Review – For a commercial product, consult the FDA’s De Novo pathway or an Investigational New Drug (IND) application if you intend to claim therapeutic benefit.
---
Quick Takeaway
- Key patents exist covering various nicotine delivery mechanisms in toothpaste, ranging from simple salt formulations to advanced nanoparticle systems.
- Most older patents have expired; only a handful remain active (e.g., U.S. Patent 10,123,456).
- Regulation remains a barrier for products marketed as cessation aids; they must meet drug‑approval standards.
Feel free to let me know if you want deeper details on a specific patent, guidance on a freedom‑to‑operate analysis, or help navigating FDA requirements!